These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 16767815)
21. Degarelix (firmagon) for prostate cancer. Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145 [No Abstract] [Full Text] [Related]
22. Androgen suppression therapy and prostate cancer: balancing the harms and the benefits. Oefelein MG Cancer; 2008 Dec; 113(12):3275-8. PubMed ID: 18988289 [No Abstract] [Full Text] [Related]
23. Long-term effects of tibolone on ocular functions in postmenopausal women. Verit FF; Oguz H; Ozkul Y; Bozkurt O Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975 [TBL] [Abstract][Full Text] [Related]
24. The LIBERATE tibolone trial in breast cancer survivors. Speroff L Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923 [No Abstract] [Full Text] [Related]
25. Raloxifene and risk for stroke based on the framingham stroke risk score. Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454 [TBL] [Abstract][Full Text] [Related]
26. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC; Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255 [TBL] [Abstract][Full Text] [Related]
27. Menopause and stroke and the effects of hormonal therapy. Lobo RA Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669 [TBL] [Abstract][Full Text] [Related]
28. Still waiting and searching for answers. Maestri E; Maltoni S; Basevi V; Marata A; Magrini N BMJ; 2008 Jan; 336(7634):7-8. PubMed ID: 18174568 [No Abstract] [Full Text] [Related]
29. Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication. Gregersen N; Jensen PT; Giraldi AE Dan Med Bull; 2006 Aug; 53(3):349-53. PubMed ID: 17092454 [TBL] [Abstract][Full Text] [Related]
30. Tibolone is not aromatized in postmenopausal women. Kloosterboer HJ Climacteric; 2008 Apr; 11(2):175; author reply 175-6. PubMed ID: 18365860 [No Abstract] [Full Text] [Related]
31. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Morris EP; Rymer J; Robinson J; Fogelman I Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410 [TBL] [Abstract][Full Text] [Related]
33. What is tibolone--and is it a SPEAR? Purdie DW Climacteric; 2002 Sep; 5(3):236-9. PubMed ID: 12419081 [No Abstract] [Full Text] [Related]
34. Benign prostatic hypertrophy: update on drug therapy. Tejani A; Musini V; Perry TL; Mintzes B; Wright JM Can Fam Physician; 2006 Sep; 52(9):1075-6, 1077-8. PubMed ID: 17279217 [No Abstract] [Full Text] [Related]
35. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study. Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505 [TBL] [Abstract][Full Text] [Related]
36. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Archer DF; Hendrix S; Ferenczy A; Felix J; Gallagher JC; Rymer J; Skouby SO; den Hollander W; Stathopoulos V; Helmond FA; Fertil Steril; 2007 Oct; 88(4):866-78. PubMed ID: 17548089 [TBL] [Abstract][Full Text] [Related]
37. Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women. Cicinelli E; Ranieri G; Maffei S; Colafiglio G; Ria R; Bellavia M; Schonauer MM Fertil Steril; 2006 Oct; 86(4):899-904. PubMed ID: 16963035 [TBL] [Abstract][Full Text] [Related]